Cost-effectiveness evidence on approved cancer drugs in Ireland: the limits of data availability and implications for public accountability.

Background: We surveyed evidence published by Ireland's National Centre for Pharmacoeconomics (NCPE) on the cost-effectiveness of cancer drugs approved for funding within the Irish public healthcare system. The purpose is threefold: to assess the completeness and clarity of publicly available cost-effectiveness data of such therapies; to provide summary estimates of that data; to consider the implications of constraints on data availability for accountability regarding healthcare resource allocation.

Methods: The National Cancer Control Programme lists 91 drug-indication pairs approved between June 2012 and July 2020.